Skip to content

A COMPREHENSIVE REPORT FOR DECISION MAKING

Oncology DRUG Intelligence

2022

Two Reports providing complete landscape on oncology drug development

RELEASED - JUNE 2022

2350

Oncology Drug Developers Worldwide

ODI 2022 is a set of Two Reports and provides Complete Solution to Identify & Connect with Largest Number of Active Oncology Drug Development Companies.

oncology Drug intelligence 2022 (Eleventh Updated Edition)

Report Covers all Aspects of Cancer Drug Development Intelligence

COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING

Oncology drug intelligence 2022
largest coverage

providing intelligence at fingertips

Countries
1

Worldwide 34 Countries Covered. Largest Coverage Guaranteed

Drug developers
1

1150 Active Clinical & 1200 Preclinical Stage Oncology Companies Profiled 

Molecules in Development
1 +

Individual Drug Mechanism of Action & Drug Target

Cancer Targets
1 +

Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies

TWO REPORTS

Intelligence @ fingertips

Provides Complete Landscape on Latest Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status in the Domain.
Drug Developers with proper funding, technologies and pipeline are only included.
No Acquired, Merged or Dormant Stage Cancer Targeting Drug Developer is included.

01

identify new opportunities

TWO Oncology reports

360 Degree Insights on Drug Development

  • 2350+ Active Cancer Drug Developers.
  • 4200+ Active Molecules in Development.
  • 1500+ Deals & Partnering Details.
  • Special coverage on CAR-T, Vaccines, ADCs, Monoclonal Antibodies, Oncolytic Viruses and Small molecule Kinase Inhibitors.
  • Emerging Technologies like Microbiome, CRISPER, Exosomes, RNAi etc., as Cancer treatment are covered.

Oncology Clinical Drug Intelligence- 2022

World's Largest Insights based on Active 1150 Clinical Stage Oncology Drug Developers
-----------------------------------------
Includes Insights on
Companies | Technologies
Pipeline | Targets | Deals | Funding

Details

Report provides an extensive coverage on Oncology Drug Development and includes World’s Largest Number of Active Clinical Stage Oncology¬†Drug Developers. (1150 Companies Profiles)

1400+ Pages provides, in-depth Analysis on

  • GLOBAL 1150 CLINICAL STAGE ONCOLOGY DRUG DEVELOPERS.
  • 2800+ CANCER TARGETING MOLECULES IN DEVELOPMENT.
  • EMERGING CANCER DRUG TARGETS & PROPERITORY TECHNOLOGIES.
  • ONCOLOGY FOCUSED DEALS & PARTNERING ACTIVITIES.
  • INDIVIDUAL COMPANY FUNDING STATUS

Report opens an immense opportunities to New Business Development.
Explore More

Show

Single Source Solution to Reach-out and connect World’s Largest Number of Active Early Stage Oncology Drug Developers. (1200 Companies).

853 Pages Report contains in-depth Analysis on

  • 1200 ACTIVE COMPANIES PROFILE
  • 1400+ CANCER TARGETING MOLECULES IN DEVELOPMENT.
  • EMERGING CANCER DRUG TARGETS & PROPERITORY TECHNOLOGIES.
  • ONCOLOGY FOCUSED DEALS & PARTNERING ACTIVITIES.
  • INDIVIDUAL COMPANY FUNDING STATUS, and much more.¬†

Report opens an immense opportunities to New Business Development.
Explore More

Show

Oncology PreClinical Drug Intelligence 2022

World's Largest Insights covering 1200 Active PreClinical Stage Oncology Drug Developers
-----------------------------------------
Includes Insights on
Companies | Technologies
Pipeline | Targets | Deals | Funding

Details

Perfect B2B Solution

Unique first in class Intelligence Report

Comparisons
Oncology Drug Intelligence 2022
Other Intelligence Sources
Clinical Stage Oncology Drug Developers
1150 Active Companies
(Companies with Active Pipeline are only Included)
600-800 Companies
(maybe mixed with non active/ diagnostic etc.)
Pre-Clinical Stage Oncology Drug Developers
1200 Active Companies
(Well Funded with clear defined early stage Pipeline)
400-600 Companies
(with many inactive and other domain companies)
Worldwide Coverage
34 Countries Included
(52% USA, 24% Europe, 20% Asia and 4% ROW)
Mainly United States and Europe Covered
Oncology Drugs in Development
4200+ Onco Targeting Drugs in Active Development
(2400+ Clinical Stage with NCT Number & 1800+ Preclinical Stage, with their Targets and mechanism of Action)
2000 – 2500 Onco Targeting Drugs
(mainly includes Clinical Stage molecules in development)
Bio-Partnering Details
1500+ Oncology Deals complete Details.
(Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation)
Limited to Database / Resource Subscribed to.
(Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals).

Further Customizationon This Report

Launch Offer Till 30 June 2022

Trusted by

BUSINESS LEADERS -WORLDWIDE